地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18327026838
邮箱:sales@amyjet.com

艾美捷科技代理VisualProtein品牌。
VisualProtein成立于2005年,致力于通过提供创新的科研产品与服务推动生物领域发展。凭借在蛋白质组学、免疫学及细胞学领域的专业深耕,不断拓宽科学研究的可能性边界。
Visual Protein的产品包括:
| 分类 | 品名 | 货号 |
| Proteomics | Western Blot Tool Box | BOX12 |
| Proteomics | Western Blot Tool Box with LuminolPen(LH03-10) | BOX12-03 |
| Proteomics | BlockPRO™ Blocking Buffer | BP01-1L |
| Proteomics | BlockPRO™ Protein-Free Blocking Buffer | BF01 |
| Proteomics | BlockPRO™ 1 Min Protein-Free Blocking Buffer | BM01 |
| Proteomics | LuminolPen™, HRP system | LH03 |
| Proteomics | LumiFlash™ Prime Chemiluminescent Substrate, HRP System | LF01-500 |
| Proteomics | LumiFlash™ Ultima Chemiluminescent Substrate, HRP System | LF08-500 |
| Proteomics | LumiFlash™ Infinity Chemiluminescent Substrate, HRP System | LF16-500 |
| Proteomics | LumiFlash™ Femto Chemiluminescent substrate, HRP System | LF24-100 |
| Proteomics | ExtractPRO™ Protein Extraction Reagent | EP05-30 |
| Proteomics | RIPA Cell Lysis Buffer | RP05 |
| Proteomics | Dual-Range™ BCA Protein Assay Kit | BC03-500 |
| Proteomics | Dual-Range™ Bradford Reagent (1X) | BR01-500 |
| Proteomics | Dual-Range™ Bradford Reagent (5X) | BR05-500 |
| Proteomics | Dual-Range™ Bradford Protein Assay Kit (5X) | BR05-500-K |
| Proteomics | VisPRO™ Blue-One Protein Stain | VB01-500 |
| Proteomics | VisPRO™ 5 Minute Protein Stain Kit | VP01 |
| Proteomics | 6X Laemmli SDS Sample Buffer, non-reducing(without beta-mercaptoethanol) | SBN06-15 |
| Proteomics | 6X Laemmli SDS Sample Buffer, reducing(with beta-mercaptoethanol) | SBR06-15 |
| Immunoassay buffer | ImmunoEX immunoassayDevelopment Kit(TBST) | IEX001 |
| Immunoassay buffer | ImmunoEX ImmunoassayDevelopment Kit (TBS) | IEX002 |
| Immunoassay buffer | ImmunoEX TBST Buffer | IE01-500 |
| Immunoassay buffer | ImmunoEX TBS Buffer | IE02-500 |
| Immunoassay buffer | mmunoEX Protein-BasedImmunoassay Buffer(TBST | IE03-500 |
| Immunoassay buffer | ImmunoEX Protein-Based lmmunoassay Buffer (TBS) | IE04-500 |
| Immunoassay buffer | ImmunoEX Protein-Free Immunoassay Buffer(TBST | IE05-500 |
| Immunoassay buffer | ImmunoEX Protein-Free Immunoassay Buffer (TBS) | IE06-500 |
| Supplement | CytoMore Cell RescueSupplement | CTO1-1BT |
| Supplement | HybriMore™ Hybridoma Culture Supplement* | HB01-1L |
| Buffer | PBS Buffer, 10X | PBS10-1L |
| Buffer | PBS Tween-20 Buffer, 10X | PBST10-1L |
| Buffer | TBS Buffer, 10X | TBS10-1L |
| Buffer | TBS Tween-20 Buffer, 10X | TBST10-1L |
| Buffer | TBS Tween-20 Buffer, 25X | TBST200P |
| Buffer | SDS-PAGE Running Buffer, 10X | RB10-1L |
| Buffer | SDS-PAGE Running Buffer, powder pack | RB500P |
| Buffer | Western Blot Transfer Buffer, 10X | WTB10-1L |
| Buffer | Western Blot Transfer Buffer, powder pack | WTB500P |
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理VisualProtein品牌"> 艾美捷科技代理VisualProtein品牌

艾美捷科技代理Serumwerk Bernburg AG品牌。
Serumwerk Bernburg AG在医药产品、医疗器械和活性药物成分的开发和生产领域,已逾60多年。Serumwerk Bernburg AG为广大科研和临床工作者提供一系列碘化物的密度梯度分离液包括:即用型、多功能型分离液。该系列产品不仅可以分离多种种属如人、灵长类、啮齿类、兔、反刍动物等来源的多种细胞、亚细胞器,而且可以分离纯化膜囊泡、病毒、蛋白质、核酸以及脂蛋白等物质。公司的产品符合美国FDA及获得欧洲cGMP标准,它们具有安全无毒、低渗透性和分离纯化效果好等特点。

艾美捷科技代理cellQART品牌细胞培养小室。
cellQART隶属于德国SABEU公司,SABEU公司是一家长期专业从事微孔滤膜和注塑成型组件的供应商。它根据客户需求的技术参数研发、生产系列产品,并制定了cellQART和FLUXX产品线标准,所有产品都在德国生产。cellQART系列6孔 、12孔和24孔细胞培养插入件及预装培养板,与大多数标准细胞培养板兼容。该产品系列提供6孔、12孔和24孔规格的PET膜,分为半透明、透明扩展培养和透明光学三种类型。插入件经过组织培养处理,无菌,并且与大多数标准细胞培养板兼容。此外,cellQART® 细胞培养插入件 还可与我们特别设计的培养板搭配使用。这些培养板提供6孔、12孔和24孔规格,无菌且预装了 cellQART® 细胞培养插入件。
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理cellQART品牌细胞培养小室"> 艾美捷科技代理cellQART品牌细胞培养小室

艾美捷科技代理JGFInneran品牌。
JGFInneran在生物技术和实验室设备领域具有显著优势,凭借高质量产品和定制化服务,赢得了广泛的市场认可。JGFInneran提供先进的控制系统,实现精确的温度、pH、溶氧控制;采用高质量材料,使用不锈钢和玻璃等耐腐蚀材料,确保设备耐用;自动化与数据记录: 支持自动化操作和实时数据记录,便于实验监控和分析。应用领域包括:生物制药: 用于单克隆抗体、疫苗等生产;生物燃料: 用于微生物发酵生产乙醇等;食品与饮料: 用于发酵工艺优化;学术研究: 为科研机构提供实验设备。
JGFInneran公司主要产品包括:
(1)生物反应器:用于细胞培养和发酵,广泛应用于生物制药、疫苗生产和生物燃料开发。
(2)发酵罐:适用于微生物和细胞培养,具备高精度控制和自动化功能。
(3)实验室设备:提供搅拌器、泵、传感器等,满足实验室的多样化需求。
(4)定制解决方案:根据客户需求,提供定制化的生物反应器和发酵罐。

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理Molecular Dimensions品牌。
Molecular Dimensions 是一家专注于为X射线晶体学和结构生物学领域提供高质量试剂、耗材和设备的公司。公司致力于支持科学家在蛋白质晶体学、小分子晶体学和材料科学等领域的研究,提供从晶体生长到数据收集的全流程解决方案。Molecular Dimensions 以其创新的产品、严格的质量控制和卓越的客户服务而闻名,已成为全球晶体学研究领域的重要供应商之一。Molecular Dimensions核心业务领域:
(1)晶体生长试剂:Molecular Dimensions 提供多种用于蛋白质和小分子晶体生长的试剂,包括结晶筛选试剂盒、缓冲液、沉淀剂和添加剂。
(2)结晶筛选试剂盒:提供多种结晶筛选试剂盒,如 JCSG+、Morpheus 和 PACT,适用于不同类型的晶体生长实验。
(3)晶体学耗材:提供用于晶体学研究的耗材,如结晶板、密封膜、样品支架和低温冷冻工具。
(4)自动化晶体成像系统:Molecular Dimensions 提供自动化晶体成像系统(如 Rock Imager),用于实时监测晶体生长过程,帮助科学家优化晶体生长条件。
(5)蛋白质纯化和结晶工具:公司提供用于蛋白质纯化和结晶的工具,如蛋白质浓缩器、透析设备和结晶板。
(6)软件和数据分析工具:Molecular Dimensions 提供用于晶体学数据分析和结构解析的软件工具,如 AceDRG 和 xia2。

艾美捷科技代理LifeSensors品牌。
LifeSensors成立于1996年,位于美国宾夕法尼亚州费城,是一家为药物发现与研究提供方法和可行性技术方法的生物技术公司。公司致力于为泛素和泛素蛋白酶体通路研究领域提供高品质
的抗体、酶、蛋白质等试剂和试剂盒,产品,是泛素研究者的好选择。
其原核和真核蛋白表达系统SUMOpro和SUMOstar已被世界范围内的学术、政府研究机构和制药、生物技术公司广泛应用。通过提供创新的研究工具,LifeSensors已成为泛素和泛素样蛋
白途径的优质供应商。
LifeSensors公司目前主要的产品有400多种,其产品主要覆盖泛素和泛素蛋白酶体通路等科学应用领域,并且产品线在不断的扩大中。公司开创了两大独家技术平台:用于细胞信号和药物
发现的泛素蛋白酶体系统(UPS),以及增强目的蛋白在大肠杆菌、酵母、昆虫和哺乳动物细胞中表达与纯化的SUMO融合表达系统。泛素蛋白酶体系统正在成为继激酶之后,药物发现的下
一个机遇,必将成为未来许多新型药物的创新来源。作为泛素蛋白领域的先驱公司,药物的发现、分析化合物以及去泛素酶和泛素化酶的高通量筛选正是LifeSensors创新技术的真正亮点。
此外,LifeSensors还为泛素的蛋白质组学提供众多定制技术服务,并且已经开发了各种各样的测定细胞中的生理底物或生物标志物的方法。
< " data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理LifeSensors品牌"> 艾美捷科技代理LifeSensors品牌
艾美捷科技代理Larova GmbH超纯脱氧核糖核苷酸(dNTPs)。
Larova GmbH位于德国,主要生产超纯脱氧核糖核苷酸(dNTPs)及预混的dNTPs。Larova可根据需求提供定制dNTP浓度及反离子的溶液,dNTP溶液提供从50 mL到1000 L的量级,包装规格为0.25 mL至200 mL。Larova也可以提供预混dNTPs,预混的超纯脱氧核糖核苷酸(dNTPs)溶液,便于在PCR应用中使用。标准预混液包含等摩尔浓度的dATP、dCTP、dGTP和dTTP,也可根据需求提供不同浓度或包含dUTP的定制预混液。产品特点包括:(1)超纯(>99.0%纯度)、(2)稳定性、(3)不含人类和大肠杆菌DNA、(4)不含DNase、RNase和蛋白酶。主要应用于长片段PCR、cDNA合成和RT-PCR、实时荧光定量PCR、标准PCR、高保真PCR。
<<<<< " data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Larova GmbH超纯脱氧核糖核苷酸(dNTPs)"> 艾美捷科技代理Larova GmbH超纯脱氧核糖核苷酸(dNTPs)

艾美捷科技代理Steraloids Inc. 全系列产品。
Steraloids致力于为研究者提供2700种不同的类固醇雄激素,雌激素,孕激素,cholestins、胆汁酸、激素和代谢产物。
Steroids for Research: 2700 different androgens, estrogens, cholestins, progestins, bile-acids, hormones, and metabolites. Synthetic of endogenous, synthesized to purified standards.
<<| 产品列表 | ||
| 产品名称 | 产品编号 | CAS# |
| 1,(5α)-ANDROSTEN-4-AZA-3-ONE-17β-(N-TERT-BUTYL-CARBOXAMIDE) | A4370-000 | CAS 98319-26-7 |
| 1, (5α)-ANDROSTEN-3, 17-DIONE | A4400-000 | CAS 571-40-4 |
| 1(5α)-ANDROSTEN-1β-METHYL-17β-OL-3-ONE | A4420-000 | CAS 153-00-4 |
| 1(5α)-ANDROSTEN-1β-METHYL-17β-OL-3-ONE ACETATE | A4421-000 | CAS No |
| 1,(5α)-ANDROSTEN-1β-METHYL-17β-OL-3-ONE ENANTHATE | A4444-000 | CAS 303-42-4 |
| 1,(5α)-ANDROSTEN-2- METHYL-17β- OL-3-ONE | A4448-200 | CAS 5197-58-0 |
| 2(5α)-ANDROSTEN-17α-METHYL, 17β-OL | A4900-000 | CAS 3275-64-7 |
| 2, (5α)-ANDROSTEN-17β-OL | A4960-000 | CAS 2639-53-4 |
| 2, (5α)-ANDROSTEN-17β-OL ACETATE | A4961-000 | CAS No |
| 4-ANDROSTEN-3α, 17α-DIOL | A5480-000 | CAS 15183-38-7 |
| 4-ANDROSTEN-3α, 17α-DIOL DIACETATE | A5490-000 | CAS No |
| 4-ANDROSTEN-3α, 17β-DIOL | A5500-000 | CAS 1852-61-5 |
| 4-ANDROSTEN-4-OL-3, 17-DIONE METHYL ETHER | A6507-000 | CAS No |
| 4-ANDROSTEN-6α-OL-3, 17-DIONE | A6520-000 | CAS 24704-84-5 |
| 5-ANDROSTEN-17β-ACETAMIDO-3β-OL ACETATE | A7320-000 | CAS No |
| 5-ANDROSTEN-17β-AMINO-3β-OL | A7400-000 | CAS 4350-66-7 |
| 5-ANDROSTEN-16α-BROMO-3β-OL-17-ONE | A7500-000 | CAS No |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE | A2080-000 | CAS 521-11-9 |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE ACETATE | A2081-000 | CAS No |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE 3-0-CARBOXYMETHYLOXIME | A2085-000 | CAS No |
| 5α-ANDROSTAN-17α-METHYL-17β-OL-3-ONE HEMISUCCINATE | A2090-000 | CAS No |
| 5β-ANDROSTAN-17β-OL-3-ONE | A3730-000 | CAS 571-22-2 |
| 5β-ANDROSTAN-17β-OL-3-ONE ACETATE | A3731-000 | CAS No |
| 5β-ANDROSTAN-17β-OL-3-ONE BENZOATE | A3733-000 | CAS No |
| A-NOR-5α-ANDROSTAN-2α, 17α-DIETHYNYL-2β, 17β-DIOL DIPROPIONATE | N0100-000 | CAS 56470-64-5 |
| 9(11), (5α)-ANDROSTEN-3, 17-DIONE | A8950-000 | CAS 15375-19-6 |
| 9(11), (5β)-ANDROSTEN-3α-OL-17-ONE | A9000-000 | CAS 571-49-3 |
| 9(11),(5β)-ANDROSTEN-3β,17α-DIOL | A8940-000 | CAS No |
| 16, (5α)-ANDROSTEN-3-ONE-3-CMO | A9258-000 | CAS No |
| 16, (5α)-ANDROSTEN-3-ONE-3-CARBOXYMETHYLOXIME : BSA | A9260-000 | CAS No |
| 16, (5α)-ANDROSTEN-3-ONE-3-CMO : HORSERADISHPEROXIDASE | A9264-000 | CAS No |
| 5, 15,-ANDROSTADIEN-3β-0L-17-ONE | A0602-000 | CAS 17921-64-1 |
| 1, 4-ANDROSTADIENE-3, 17-DIONE | A0100-000 | CAS 897-06-3 |
| 1, 4-ANDROSTADIEN-3, 17-DIONE 17-ETHYLENEKETAL | A0110-000 | CAS 2398-63-2 |
| 3, 5-ANDROSTADIEN-17β-OL | A0353-000 | CAS 2602-86-0 |
| 3, 5-ANDROSTADIEN-3-OL-17-ONE 3-ETHYL ETHER | A0380-000 | CAS 972-46-3 |
| 4, 6-ANDROSTADIEN-17α-METHYL-17β-OL-3-ONE | A0402-000 | CAS No |
| 5, 16-ANDROSTADIEN-17-CYANO-3β-OL | A0630-000 | CAS No |
| 1, 4-ANDROSTADIEN-17β-OL-3-ONE GLUCURONIDE | A0207-200 | CAS No |
| 1, 4-ANDROSTADIEN-17α-METHYL-17β-OL-3-ONE | A0130-040 | CAS 72-63-9 |
| 1, 4-ANDROSTADIEN-17α-METHYL-6β, 17β-DIOL-3-ONE-6-ACETATE | A0125-080 | CAS No |
| 5, 16-ANDROSTADIEN-3β-OL-17β-CARBOXYLIC ACID 3-ACETATE | A0681-000 | CAS No |
| 5, 16-ANDROSTADIEN-3β-OL-17β-CARBOXYLIC ACID ETHYL ESTER | A0685-000 | CAS No |
| 5, 16-ANDROSTADIEN-3β-OL-17β-CARBOXYLIC ACID METHYL ESTER | A0689-000 | CAS No |
| 5, 16-ANDROSTADIEN-3-ONE-17β-CARBOXYLIC ACID | A0695-000 | CAS No |
| 1, 4-ANDROSTADIEN-17α-OL-3-ONE | A0190-000 | CAS No |
| 1, 4-ANDROSTADIEN-6β,17β-DIOL-3-ONE | A0085-000 | CAS No |
| 4, 16-ANDROSTADIEN-3α-OL | A0555-000 | CAS 6306-63-0 |
| 1, 4-ANDROSTADIEN-17β-OL-3-ONE-2,4,6,6-d4 | A0200-040 | CAS 846-48-0 |
| 1, 4, 6-ANDROSTATRIEN-17β-OL-3-ONE ACETATE | A4201-000 | CAS No |
| 1, 4, 7-ANDROSTATRIEN-17β-OL-3-ONE | A4250-000 | CAS No |
| 4-CHOLESTEN-3β-OL ACETATE | C6101-000 | CAS No |
| 4-CHOLESTEN-3β-OL BENZOATE | C6103-000 | CAS No |
| 4-CHOLESTEN-2α-OL-3-ONE | C6180-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL 3-HEMISUCCINATE | C6520-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL 3-OLEATE | C6525-000 | CAS No |
| 5-CHOLESTEN-3, 25-DIOL, 25-SULPHATE, SODIUM SALT | C6538-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL-7-ONE | C6550-000 | CAS No |
| 5-CHOLESTEN-3β, 25-DIOL-7-ONE ACETATE | C6551-000 | CAS No |
| 5-, 25R-CHOLESTEN-3β, 26-DIOL | C6570-000 | CAS 20380-11-4 |
| 5-CHOLESTEN-24(S), 25-EPOXY-3β-OL | C6640-000 | CAS 77058-74-3 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ~78% | C6680-000 | CAS 83-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL -25,26,26,26,27,27,27 -D7 | C6680-015 | CAS 83-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ~54% | C6680-050 | CAS 83-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ~78% | C6680-080 | CAS 000083-46-5 |
| 5-CHOLESTEN-24β-ETHYL-3β-OL ACETATE | C6681-000 | CAS 000915-05-9 |
| 5-CHOLESTEN-24α-ETHYL-3β-OL CHLOROFORMATE | C6683-000 | CAS No |
| 5-CHOLESTEN-24-ETHYL-3-OL-7-ONE | C6684-000 | CAS 2034-74-4 |
| 5-CHOLESTEN-24(28)-ETHYLIDENE-3β-OL | C6685-000 | CAS 17605-67-3 |
| 5-CHOLESTEN-25-FLUORO-3βOL | C6688-000 | CAS No |
| 5-CHOLESTEN-24α-METHYL 3β-OL | C6700-000 | CAS 474-62-4 |
| 5-CHOLESTEN-24α-METHYL 3β-OL-30% 24β | C6700-010 | CAS 474-62-4 |
| 5-CHOLESTEN-24α-METHYL 3β-OL-BENZOATE | C6703-000 | CAS No |
| 5-CHOLESTEN-6-NITRO-3β-OL ACETATE | C6711-000 | CAS No |
| 5-CHOLESTEN-6-NITRO-3β-OL BENZOATE | C6713-000 | CAS No |
| 5-CHOLESTEN-3α-OL | C6730-000 | CAS No |
| 5-CHOLESTEN-3α-OL ACETATE | C6731-000 | CAS No |
| 5-CHOLESTEN-3β-OL | C6760-000 | CAS 57-88-5 |
| 5-CHOLESTEN-3β-OL-25,26,26,26,27,27,27-D7 | C6760-020 | CAS 57-88-5 |
| 5-CHOLESTEN-3β-OL ACETATE | C6761-000 | CAS 604-35-3 |
| 5-CHOLESTEN-3β-OL ACETOACETATE | C6762-000 | CAS No |
| 5-CHOLESTEN-3β-OL N-BUTYRATE | C6775-000 | CAS 521-13-1 |
| 5-CHOLESTEN-3β-OL BENZOATE | C6770-000 | CAS 604-32-0 |
| 5-CHOLESTEN-3-OL CAPROATE | C6780-000 | CAS No |
| 5-CHOLESTEN-3β-OL CAPRYLATE | C6785-000 | CAS No |
| 5-CHOLESTEN-3β-OL-(25R)CARBOXYLIC ACID | C6786-000 | CAS No |
| 5-CHOLESTEN-3β-OL-(25S)CARBOXYLIC ACID | C6787-000 | CAS No |
| 5-CHOLESTEN-3β-OL CHLOROACETATE | C6790-000 | CAS 3464-50-4 |
| 5-CHOLESTEN-3β-OL CHLOROFORMATE | C6795-000 | CAS 7144-08-3 |
| 5-CHOLESTEN-3β-OL CINNAMATE | C6800-000 | CAS 1990-11-0 |
| 5-CHOLESTEN-3β-OL N-DECYLATE | C6805-000 | CAS 1183-04-6 |
| 5-CHOLESTEN-3-OL DOCOSAHEXAENOATE(4,7,10,13,16,19) | C6807-000 | CAS No |
| 5-CHOLESTEN-3β-OL ETHYL ETHER | C6812-000 | CAS 98-61-96 |
| 5-CHOLESTEN-3β-OL FORMATE | C6815-000 | CAS 4351-55-7 |
| 5-CHOLESTEN-3β-OL GLUCOSIDURONATE, SODIUM SALT | C6821-000 | CAS No |
| 5-CHOLESTEN-3β-OL HEMISUCCINATE | C6823-000 | CAS 1510-21-0 |
| 5-CHOLESTEN-3β-OL N-HEPTYLATE | C6825-000 | CAS 1182-07-6 |
| 5-CHOLESTEN-3β-OL ISO-BUTYRATE | C6840-000 | CASNoCH Groups C31 H52 |
| 5-CHOLESTEN-3β-OL LAURATE | C6845-000 | CAS 190-8-11-8 |
| 5-CHOLESTEN-3β-OL METHYLCARBONATE | C6855-000 | CAS 15507-52-5 |
| 5-CHOLESTEN-3β-OL METHYL ETHER | C6860-000 | CAS 1174-92-1 |
| 5-CHOLESTEN-3β-OL MYRISTATE | C6865-000 | CAS 1989-52-2 |
| 5-CHOLESTEN-3β-OL OLEATE | C6870-000 | CAS 303-43-5 |
| 5-CHOLESTEN-3β-OL OLEYL ETHER | C6871-000 | CAS No |
| 5-CHOLESTEN-3β-OL PALMITATE | C6875-000 | CAS No |
| 5-CHOLESTEN-3β-OL PELARGONATE | C6880-000 | CAS 1182-66-7 |
| 5-CHOLESTEN-3-OL PHENYLPROPIONATE | C6890-000 | CAS 14914-99-9 |
| 5-CHOLESTEN-3β-OL PROPIONATE | C6895-000 | CAS 633-31-8 |
| 5-CHOLESTEN-3β-OL PYRIDINIUM SULPHATE | C6903-000 | CAS No |
| 5-CHOLESTEN-3β-OL STEARATE | C6904-000 | CAS 35602-69-8 |
| 5-CHOLESTEN-3β-OL SULPHATE, SODIUM SALT | C6905-000 | CAS 2864-50-8 |
| 5-CHOLESTEN-3β-OL P-TOLUENESULPHONATE | C6910-000 | CAS 1182-65-6 |
| 5-CHOLESTEN-3β-OL SULPHATE TRIETHYL AMMONIUM SALT | C6911-000 | CAS No |
| 5-CHOLESTEN-3β-OL N-VALERATE | C6915-000 | CAS 1182-07-6 |
| 5-CHOLESTEN-3β-OL-7-ONE | C6970-000 | CAS 566-28-9 |
| 5-CHOLESTEN-3β-OL-7-ONE ACETATE | C6971-000 | CAS No |
| 5-CHOLESTEN-3β-OL-7-ONE BENZOATE | C6973-000 | CAS No |
| 5-CHOLESTEN-3-OL-7-ONE-7-CARBOXYMETHYLOXIME | C6980-000 | CAS 566-28-9 |
| 5-CHOLESTEN-3-OL-22-ONE | C7020-000 | CAS 19243-30-2 |
| 5-CHOLESTEN-3-OL-22-ONE ACETATE | C7021-000 | CAS No |
| 5-CHOLESTEN-3β- OL-24-ONE | C7030-000 | CAS 17752-16-8 |
| 5-CHOLESTEN-3-ONE | C7050-000 | CAS 601-54-7 |
| 5-CHOLESTEN-7-ONE | C7060-000 | CAS No |
| 5-CHOLESTEN-3, 7α, 25-TRIOL | C7085-000 | CAS No |
| 5-CHOLESTEN-3β, 16β, 26(25R)-TRIOL | C7090-000 | CAS No |
| 5-CHOLESTEN-3, 17α, 20α-TRIOL | C7100-000 | CAS No |
| N-ACETYL-5-METHOXYTRYPTAMINE-α,α,β,β-D4 | Z0600-000 | CAS 73-31-4 |
| 5-CHOLESTEN-3β, 4α-DIOL | C6400-000 | CAS 34310-86-6 |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Steraloids"> Steraloids
<艾美捷科技代理Aneufast品牌全系列产品
Aneufast是一家专业生产诊断非整倍体染色体试剂盒的生物公司。QF-PCR试剂盒Aneufast公司的核心产品。Aneufast™ QF-PCR试剂盒包含六组多重标记系统,基于短串联重复序列(STRs)扩增技术,可同步检测精选微卫星位点及性别决定基因(Amelogenin-SRY)。该设计通过单次反应实现多染色体同步筛查,显著提升检测效率。此标记组合可精准识别13、18、21号常染色体及X、Y性染色体的非整倍体异常。

Aneufast™ QF-PCR试剂盒具有以下特点:
● 五色荧光DNA片段分析系统:采用五重荧光标记技术,实现单次电泳中13/18/21/X/Y染色体STR标记的同步检测与区分;
● 即用型PCR预混体系:含热启动聚合酶及优化缓冲液,操作仅需 "加DNA→扩增" 两步;
● 超快速检测流程:样本到结果仅需3.5小时
● 染色体特定位点备份设计:每套试剂盒额外提供 13/18/21/X/Y染色体专属STR标记(独立分装)
● 全平台兼容性:经优化适配ABI全系列基因分析仪,如3500/3500xL Dx,SeqStudio Flex和7500 Fast Dx
● 国际质量认证:符合欧盟体外诊断指令98/79/EC;通过 ISO 9001:2000 及 ISO 13485:2003 医疗器械生产双认证
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:13212737804
传真:18771997407
邮箱:sales@amyjet.com
0.1823